Is Zimmer Biomet Holdings (ZBH) Undervalued Following New Credit Facilities And Growth Plans?
Zimmer Biomet Holdings (ZBH) stock is back in focus after the company entered new unsecured revolving credit facilities totaling up to $2.75b, a move that refreshes its liquidity framework for general corporate purposes.
See our latest analysis for Zimmer Biomet Holdings.
Zimmer Biomet Holdings’ latest refinancing comes as momentum in the stock has picked up in the short term, with a 7 day share price return of 4.42% and a 30 day share price return of 3.60%. However, the 1 year total shareholder return is down 1.59% and the 3 year and 5 year total shareholder returns are down 34.03% and 35.91% respectively, which suggests recent optimism is still set against a longer period of weaker investor outcomes.
If you are weighing Zimmer Biomet’s position in your portfolio, this can also be a useful moment to broaden your search and look at 41 healthcare AI stocks.
Zimmer Biomet’s fresh credit lines and mixed long term returns leave you weighing a simple trade off: step in after this refinancing tailwind, or hold off in case a weaker share price offers a more comfortable entry. Next comes what the valuation says.
Most Popular Narrative: 7.5% Undervalued
Zimmer Biomet Holdings is trading at a last close of $91.34 against a widely followed fair value estimate of $98.70. This frames the refinancing debate around whether current pricing already reflects its long term robotics and orthopedics story.
The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.
Want to see what sits behind that fair value gap for Zimmer Biomet? The narrative leans heavily on steadier revenue growth, rising margins and a future earnings multiple that must all line up cleanly. Curious which of those assumptions really carries the weight in the model?
Result: Fair Value of $98.70 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Zimmer Biomet faces pricing pressure and intense competition in robotics, and any delay or setback with acquisitions such as Paragon 28 or Monogram could quickly challenge this optimism.
Find out about the key risks to this Zimmer Biomet Holdings narrative.
Next Steps
That mix of optimism and concern around Zimmer Biomet means opinions will likely stay divided, so use this momentum to review the data yourself and see how the story stacks up against 3 key rewards and 2 important warning signs
Looking for more ideas beyond Zimmer Biomet?
Before moving on from Zimmer Biomet, take a few minutes to scan other stocks that might fit your goals, so you are not leaving better fits undiscovered.
- Target potential mispricings by reviewing companies that screen well for quality and valuation using the 44 high quality undervalued stocks.
- Prioritise resilience by checking out the 76 resilient stocks with low risk scores to see which businesses stand out on stability and risk checks.
- Get ahead of the crowd by browsing the screener containing 19 high quality undiscovered gems to see which underfollowed stocks still show strong fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com